Stephanie Y. Tsai

Stephanie Y. Tsai

Auto-generated profile, based on publicly available information

Stephanie Y. Tsai

Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SSScott Silvey
Scott Silvey
NPNilang Patel
Nilang Patel
STStephanie Y. Tsai
Stephanie Y. Tsai
MNMahum Nadeem
Mahum Nadeem
RSRichard K. Sterling
Richard K. Sterling
JBJasmohan Bajaj
Jasmohan Bajaj
INTRODUCTION: Spontaneous bacterial peritonitis (SBP) bacteriology has changed over time. Reappraisal of primary SBP prophylaxis showed an increased rate of resistance in patients on primary prophylaxis with resultant discontinuation of this prophylaxis throughout the Veterans Affairs (VA). We aimed to re-evaluate the risk-benefit ratio of secondary SBP prophylaxis (SecSBPPr). METHODS: Using validated International Classification of Diseases -9/10 codes, we used the VA Corporate Data Warehouse and the Non-VA National TriNetX database to identify patients in 2 different large US systems who survived their first SBP diagnosis (with chart review from 2 VA centers) between 2009 and 2019. We evaluated the prevalence of SecSBPPr and compared outcomes between those who started on SecSBPPr vs not. RESULTS: We identified 4,673 veterans who survived their index SBP episode; 54.3% of whom were prescribed SecSBPPr. Multivariable analysis showed higher SBP recurrence risk in those on vs off SecSBPPr (hazards ratio 1.63 [1.40–1.91], P < 0.001). This was accompanied by higher fluoroquinolone resistance odds in SecSBPPr patients (odds ratio = 4.32 [1.36–15.83], P = 0.03). In TriNetX, we identified 6,708 patients who survived their index SBP episode; 48.6% were on SecSBPPr. Multivariable analysis similarly showed SecSBPPr increased SBP recurrence risk (hazards ratio 1.68 [1.33–1.80], P < 0.001). Both data sets showed higher SBP recurrence trends over time in SecSBPPr patients. Results remained consistent at 6-month and 2-year timepoints. DISCUSSION: In 2 national data sets of >11,000 patients with SBP, we found that SecSBPPr was prescribed in roughly half of patients. When initiated, SecSBPPr, compared with no prophylaxis after SBP, increased the risk of SBP recurrence in multivariable analysis by 63%–68%, and this trend worsened over time. SecSBPPr should be reconsidered in cirrhosis.

7 August 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
STStephanie Y. Tsai
Stephanie Y. Tsai
GUGiselle B. Uwera
Giselle B. Uwera
BRBethany Roehm
Bethany Roehm
APAmbarish Pandey
Ambarish Pandey
LVLisa B. VanWagner
Lisa B. VanWagner
Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly recognized as a central component of cardiovascular–kidney–metabolic syndrome, reflecting shared pathways of insulin resistance, inflammation, and fibrotic injury that drive multiorgan disease. Affecting more than one third of adults worldwide, MASLD frequently coexists with CKD and cardiovascular disease and is associated with higher risks of kidney function decline, cardiovascular (CV) events, and mortality. Hepatic steatosis and fibrosis may amplify systemic metabolic stress and endothelial dysfunction, contributing to progressive kidney injury and adverse cardiometabolic outcomes. Despite this biologic and epidemiologic overlap, MASLD remains underrecognized in nephrology and cardiology practice. This gap represents a missed opportunity to identify patients at a high risk of multiorgan complications early. Noninvasive liver fibrosis assessment, integrated with kidney and CV risk stratification, offers a practical approach to identifying patients who may benefit from intensified preventive strategies. Lifestyle modification remains foundational, while emerging pharmacotherapies, including glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, mineralocorticoid receptor antagonists, and liver-directed agents, demonstrate potential cross-organ benefits. Coordinated management targeting metabolic dysfunction may slow the progression of kidney disease while improving hepatic and CV outcomes. This review highlights the clinical intersection of MASLD, CKD, and cardiovascular disease and proposes a multidisciplinary framework for screening and management. Recognizing MASLD as part of systemic cardiovascular–kidney–metabolic disease can inform risk stratification, guide therapy selection, and support earlier intervention to mitigate the triple burden of liver, kidney, and CV complications.